A dissertation submitted to the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, in fulfilment of the requirements for the degree of Master of Science in Medicine in the specialty of Virology, June 2018 / The discovery of broad and potent neutralizing HIV antibodies (bNAbs) has opened up new opportunities of passive immunization for HIV-1 prevention. In this study, we have engineered CAP256-VRC26.25, a V1V2 bNAb that neutralizes 70% of clade C viruses, as a single domain antibody (sdAb). These small antigen binding entities are derived from naturally occurring heavy chain only antibodies present in members of the dromedary families, and are characterized by the absence of a light chain, long complementarity-determining regions (CDR) heavy (H) chain 3 and high stability. Since CAP256.25 contains a highly charged and protruding CDR-H3 that binds mainly through its heavy chain, we hypothesized that it may function well as an sdAb. Multiple camelization approaches to engineer CAP256.25 as a sdAb were tested in silico utilising structural modelling software. Parameters such as germline sequence homology, hydrophobicity and solubility, folding energy, torsion angles and native conformation of CAP256.25 in complex with its binding epitope were major factors considered during the modelling process. Four CAP256.25 sdAb derivatives were generated from parental antibody, the mut_0 or a wild type (WT), which was used as a base line for downstream optimization. CAP256.25 mut_4 in which residues involved in LC interactions were replaced with residues strongly conserved in camel sdAbs, which minimize hydrophobic interface of the sdAb. Mut_8 variant, which included four additional substitutions to increase solubility and mut_9 contained a single additional mutation at the base of CDR-H3 to improve the energetic landscape of sdAb. All genes were synthesized and sub-cloned into a mammalian expression vector and recombinant proteins expressed in HEK293T cell line, and purified by Immobilized Metal Ion Affinity Chromatography (IMAC) and Fast Protein Liquid Chromatography (FPLC). CAP256.25_mut0 expression was below the detectable level and whilst mut_4 expressed at low levels, it showed no neutralization activity. CAP256.25 sdAb mut_8 and mut_9 expressed at significantly lower levels compared to m36, a previously described sdAb used a positive control. Nevertheless CAP256.25mut_8 sdAb showed neutralization capability although it lost significant potency in comparison to the parental antibody, yet still within the therapeutic window of the VRC01 bNAb. Importantly, CAP256.25 sdAb was unable to neutralize the K169E mutant confirming that it retained specificity for the V2 epitope. These data suggest that camelization of human antibodies is possible although further engineering is required to increase expression and improve stability. As such, sdAb engineering could be an encouraging step for the generation of small antigen binding fragments for future therapeutic purposes including topical delivery at mucosal surfaces, to interrupt or block sexual transmission of HIV. / XL2018

Clostridium difficile is the leading cause of death from gastrointestinal infections in Canada. Current antiobiotic treatment is non-ideal due to the high incidence of relapse and the rise in hyper-virulent antibiotic-resistant strains. Surface layer proteins (SLPs) cover the entire bacterial surface and mediate adherence to host cells. Passive and active immunization against SLPs greatly enhances survival in hamsters, suggesting that antibody-mediated bacterial neutralization may be an effective alternative therapeutic strategy. Using a recombinant-antibody phage display library, and SLPs from strain QCD 32g58 as bait antigen, we isolated and extensively characterized 11 SLP-specific recombinant single-domain antibodies (sdAbs), in terms of affinity and specificity, intrinsic stability, and ability to inhibit cell motility. Several sdAbs exhibit promising characteristics for a potential oral therapeutic based on their high affinity, high thermal stability, and resistance to pepsin digestion. Our study provides the basis of a proof-of-principle model with which to develop specific, broadly neutralizing and intrinsically stable antibodies for the oral therapy of C. difficile infections, as an alternative to conventional antibiotic treatment.

Clostridium difficile is the leading cause of death from gastrointestinal infections in Canada. Current antiobiotic treatment is non-ideal due to the high incidence of relapse and the rise in hyper-virulent antibiotic-resistant strains. Surface layer proteins (SLPs) cover the entire bacterial surface and mediate adherence to host cells. Passive and active immunization against SLPs greatly enhances survival in hamsters, suggesting that antibody-mediated bacterial neutralization may be an effective alternative therapeutic strategy. Using a recombinant-antibody phage display library, and SLPs from strain QCD 32g58 as bait antigen, we isolated and extensively characterized 11 SLP-specific recombinant single-domain antibodies (sdAbs), in terms of affinity and specificity, intrinsic stability, and ability to inhibit cell motility. Several sdAbs exhibit promising characteristics for a potential oral therapeutic based on their high affinity, high thermal stability, and resistance to pepsin digestion. Our study provides the basis of a proof-of-principle model with which to develop specific, broadly neutralizing and intrinsically stable antibodies for the oral therapy of C. difficile infections, as an alternative to conventional antibiotic treatment.

Clostridium difficile is the leading cause of death from gastrointestinal infections in Canada. Current antiobiotic treatment is non-ideal due to the high incidence of relapse and the rise in hyper-virulent antibiotic-resistant strains. Surface layer proteins (SLPs) cover the entire bacterial surface and mediate adherence to host cells. Passive and active immunization against SLPs greatly enhances survival in hamsters, suggesting that antibody-mediated bacterial neutralization may be an effective alternative therapeutic strategy. Using a recombinant-antibody phage display library, and SLPs from strain QCD 32g58 as bait antigen, we isolated and extensively characterized 11 SLP-specific recombinant single-domain antibodies (sdAbs), in terms of affinity and specificity, intrinsic stability, and ability to inhibit cell motility. Several sdAbs exhibit promising characteristics for a potential oral therapeutic based on their high affinity, high thermal stability, and resistance to pepsin digestion. Our study provides the basis of a proof-of-principle model with which to develop specific, broadly neutralizing and intrinsically stable antibodies for the oral therapy of C. difficile infections, as an alternative to conventional antibiotic treatment.

La recherche de nouvelles molécules à visée thérapeutique ou diagnostic ciblant les récepteurs membranaires incluant les RCPGs, les récepteurs à tyrosine kinase et les canaux ioniques sont au coeur des recherches investies par les entreprises pharmaceutiques. Dans ce projet nous avons étudié et caractérisé des domaines variables de chaîne lourde d'anticorps de lamas (sdAbs) qui peuvent contourner certaines limites liées à l'utilisation des anticorps monoclonaux ou des petites molécules. En effet, de par leurs particularités structurales qui les rendent particulièrement intéressants en termes de stabilité, d'affinité et de reconnaissance d'antigène, les sdAbs représentent etre une alternative prométeuse. Dans ce manuscrit sont exposés les travaux effectués sur les récepteurs aux tyrosines kinases appartenant à la famille des ErbBs et les récepteurs au glutamate mGluRs (RCPG). En plus d'avoir sélectionné des sdAbs hautement spécifiques de ces différents antigènes, ces molécules ont également montré des caractéristiques très étonnantes et inattendues. En effet, la majeure partie des sdAbs sélectionnés présentent une spécificité pour une conformation du récepteur particulière (forme active ou inactive). Cette particularité très pertinente nous ouvre un spectre d'application très diversifié, car elle permet de cibler et d'analyser les récepteurs dans ces différents états d'activation. Ajouté à cela, certains sdAbs possèdent une activité de modulateur allostérique, voir même présentent un effet agoniste. Ces résultats très encourageants nous ouvrent de nouvelles perspectives, et ces molécules représentent une nouvelle approche pour la modulation et l'étude des ces récepteurs. / The research for new therapeutic or diagnostic molecules targeting membrane receptors, including GPCRs, tyrosine kinase receptors and ion channels are the heart of the research invested by pharmaceutical companies. In this project we used the variable domain of llama antibody heavy chain also called single domain antibodies (sdAbs) that can bypass some limitations to the use of monoclonal antibodies or small molecules. Indeed, because of their structural features that make them particularly interesting in terms of stability, affinity and antigen recognition, sdAbs represent a very promising candidates that can be used in various fiels of application: as fluorescent probes , screening tools , or therapeutic molecules. In this manuscript are exposed the work performed on the tyrosine kinases receptor belonging to the ErbBs family and metabotropic glutamate receptors, mGluRs (GPCRs).We selected very highly specific sdAbs directed against antigen of interest, but these molecules have also shown very surprising and unexpected particularities. Indeed, most of the selected sdAbs exhibit specificity for a particular conformation of the receptor (active or inactive form). This very relevant feature opens an highly diversified application spectrum, because it allows to identify and analyze these receptors in different states of activation. Added to this, some sdAbs present an allosteric modulator activity, or even present an agonist effect. These encouraging results open up new perspectives, and these molecules represent a new approach for modulation and study of these membrane receptors.

No description available.